Proteon Therapeutics Inc (PRTO) Given Average Rating of “Hold” by Analysts
Proteon Therapeutics Inc (NASDAQ:PRTO) has earned a consensus rating of “Hold” from the nine analysts that are presently covering the company. Eight analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $3.75.
PRTO has been the topic of several analyst reports. Maxim Group set a $6.00 price objective on Proteon Therapeutics and gave the stock a “buy” rating in a research note on Thursday, May 4th. Zacks Investment Research raised Proteon Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price objective on the stock in a research note on Tuesday, March 21st. HC Wainwright set a $3.00 price objective on Proteon Therapeutics and gave the stock a “hold” rating in a research note on Saturday, May 13th. Finally, Robert W. Baird reissued a “neutral” rating and set a $3.00 price objective on shares of Proteon Therapeutics in a research note on Thursday, March 16th.
Shares of Proteon Therapeutics (NASDAQ:PRTO) traded down 3.85% during midday trading on Friday, reaching $1.25. The company had a trading volume of 124,400 shares. Proteon Therapeutics has a 52 week low of $1.20 and a 52 week high of $11.45. The stock has a 50-day moving average of $1.46 and a 200 day moving average of $3.16. The firm’s market capitalization is $20.75 million.
Proteon Therapeutics (NASDAQ:PRTO) last issued its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.43) by $0.04. On average, analysts anticipate that Proteon Therapeutics will post ($1.64) earnings per share for the current year.
Several hedge funds and other institutional investors have recently made changes to their positions in PRTO. Vanguard Group Inc. raised its position in shares of Proteon Therapeutics by 24.3% in the first quarter. Vanguard Group Inc. now owns 237,929 shares of the biopharmaceutical company’s stock valued at $416,000 after buying an additional 46,568 shares during the period. Perceptive Advisors LLC acquired a new position in shares of Proteon Therapeutics during the fourth quarter valued at about $635,000. Pharmstandard International S.A. acquired a new position in shares of Proteon Therapeutics during the fourth quarter valued at about $2,214,000. Baker BROS. Advisors LP acquired a new position in shares of Proteon Therapeutics during the third quarter valued at about $2,786,000. Finally, Spark Investment Management LLC acquired a new position in shares of Proteon Therapeutics during the third quarter valued at about $107,000. Institutional investors and hedge funds own 49.28% of the company’s stock.
Proteon Therapeutics Company Profile
Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.
Receive News & Ratings for Proteon Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.